Pulmonary Large Cell Neuroendocrine Carcinoma clinical trials

Explore recruiting pulmonary large cell neuroendocrine carcinoma clinical trials.

Recruiting pulmonary large cell neuroendocrine carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Pulmonary Large Cell Neuroendocrine Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) – DUPLE trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

Spain, Belgium, Germany, France, Sweden, Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Pulmonary Large Cell Neuroendocrine Carcinoma trials by city

Pulmonary Large Cell Neuroendocrine Carcinoma clinical trials

Recruiting pulmonary large cell neuroendocrine carcinoma studies right now

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Also recruiting in Europe

A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maintenance in patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC) – DUPLE trial

DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendocrine cancers

Pulmonary Large Cell Neuroendocrine Carcinoma trials by city

Other conditions